Khan, Kamal
Zech, Michael
Morgan, Angela T.
Amor, David J.
Skorvanek, Matej
Khan, Tahir N.
Hildebrand, Michael S.
Jackson, Victoria E.
Scerri, Thomas S.
Coleman, Matthew
Rigbye, Kristin A.
Scheffer, Ingrid E.
Bahlo, Melanie
Wagner, Matias
Lam, Daniel D.
Berutti, Riccardo
Havránková, Petra
Fečíková, Anna
Strom, Tim M.
Han, Vladimir
Dosekova, Petra
Gdovinova, Zuzana
Laccone, Franco
Jameel, Muhammad
Mooney, Marie R.
Baig, Shahid M.
Jech, Robert
Davis, Erica E.
Katsanis, Nicholas
Winkelmann, Juliane
Funding for this research was provided by:
National Institutes of Health (P50DK096415)
National Institutes of Health (MH106826)
Grantová Agentura České Republiky (GACR16-13323S)
Deutsche Forschungsgemeinschaft (LA 3830/1-1)
National Health and Medical Research Council (ID:1127144)
National Health and Medical Research Council (1105008)
National Health and Medical Research Council (1054618)
National Health and Medical Research Council (1102971)
National Health and Medical Research Council (1063799)
Article History
Received: 14 January 2019
Accepted: 15 April 2019
First Online: 30 April 2019
Disclosure
: N.K. is a paid consultant for and holds significant stock in Rescindo Therapeutics, Inc. The other authors declare no conflicts of interest.